Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Pancreatic Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
25 drugs · 152 active trials
4 drugs · 116 active trials
8 drugs · 222 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 14 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tretinoin | Phase 2 | Phase 2 | 3 | 1 | 0 | 5 | 0 | — | — | Jan 15, 2016 |
| Levoleucovorin | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Jan 13, 2021 |
| KRAS G12D Inhibitor HRS-4642 | Phase 2 | Phase 2 | 3 | 3 | 0 | 3 | 0 | — | — | Jun 17, 2024 |
| Metformin | Phase 2 | Phase 2 | 2 | 0 | 0 | 13 | 0 | — | — | 2010-07 |
| Dasatinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 9 | 0 | — | — | 2007-04 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 2 | 1 | 0 | 9 | 0 | — | — | 2007-03 |
| Vismodegib | Phase 2 | Phase 2 | 2 | 0 | 0 | 8 | 0 | — | — | Mar 31, 2009 |
| Tremelimumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 6 | 0 | — | — | Mar 25, 2015 |
| Dostarlimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Jul 23, 2020 |
| Ramucirumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Jun 29, 2016 |
| Cediranib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | 2010-05 |
| Futibatinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jun 1, 2021 |
| Ipilimumab/Nivolumab Regimen | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jun 9, 2023 |
| Serplulimab | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 10, 2024 |
| Zolbetuximab | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Mar 15, 2019 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 1 | 1 | 0 | 11 | 0 | — | — | 2010-10 |
| Niraparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 10 | 0 | — | — | Aug 29, 2017 |
| Bortezomib | Phase 2 | Phase 2 | 1 | 1 | 0 | 9 | 0 | — | — | 2002-12 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | 1999-03 |
| Veliparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | Apr 20, 2009 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | Jun 6, 2014 |
| Cobimetinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | Jul 5, 2017 |
| Doxorubicin | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2007-08 |
| Lenvatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Feb 12, 2019 |
| Selumetinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2006-08 |
| Talazoparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Jan 3, 2011 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 1996-02 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2012-07 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Nov 9, 2020 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Jan 18, 2016 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2010-07 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Dec 8, 2021 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 19, 2014 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Entrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Nov 19, 2015 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 1, 2019 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2003-02 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Pemigatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jun 14, 2022 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Sotorasib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Sep 13, 2022 |
| Streptozocin | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-08 |
| Valproic Acid | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2011-06 |
| Verteporfin | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | May 31, 2017 |
| Avutometinib And Defactinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 1, 2026 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.